ProCE Banner Activity


Targeting Moderate to Severe Psoriasis: Novel Treatments on the Horizon


Patients with psoriasis experience disruptions to their daily functioning, with higher disease severity associated with reduced quality of life. Despite many available options for managing moderate to severe psoriasis, the condition continues to be undertreated and patients’ expectations often remain unmet. Fortunately, novel small molecule agents targeting new pathways are showing promise in enhancing patient care, especially those focusing on the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) signaling pathways. This includes JAK inhibitors and a recently approved tyrosine kinase 2 (TYK2) inhibitor. Tune in to this on-demand webcast to get expert faculty insights on recent clinical trial evidence and therapeutic considerations for the expanding treatment landscape of moderate to severe psoriasis.

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: January 17, 2023

Expiration: January 16, 2024

No longer available for credit.



Steven Feldman

Steven Feldman, MD, PhD

Professor of Dermatology, Pathology and Social Sciences & Health Policy
Wake Forest University School of Medicine
Winston-Salem, North Carolina

Kristine Kucera

Kristine Kucera, PA-C, MPAS, DHS

Physician Assistant
Bare Dermatology
Dallas, Texas
Adjunct Assistant Professor
UNT Health Science Center, PA Program
Ft. Worth, Texas

Provided by

ProCE Banner


This activity is supported by an educational grant from

Bristol Myers Squibb

Target Audience

NPs and PAs who practice in dermatology

Learning Objectives

After completing this activity, learners should be better able to:

  • Identify novel agents for moderate to severe psoriasis and their selectivity within the JAK-STAT pathway 

  • Detail key elements of agents targeting the JAK-STAT pathway that differentiate their place in therapy from currently available treatments for moderate to severe psoriasis

  • Educate patients on the safety profile differences for TYK2 and JAK inhibitors for moderate to severe psoriasis


All faculty and planners participating in continuing education activities sponsored Partners for Advancing Clinical Education (PACE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PACE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Victoria Garcia-Albea, NP, DCNP: consultant/advisor/speaker: Sanofi-Genzyme.

Steven Feldman, MD, PhD: consultant/speaker: AbbVie, Accordant, Almirall, Alvotech, Amgen, Arcutis, Arena, Argenx, Biocon, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Forte, Helsinn, Janssen, Leo, Lilly, Mylan, Novartis, Pfizer, Samsung, Sanofi, Sun Pharma, Union Chimique Belge (UCB), vTv Therapeutics, Voluntis; researcher: Galderma, Janssen, Lilly, Pfizer, Regeneron; stock/stock options: Sensal Health.

Kristine Kucera, PA-C, MPAS, DHSc: consultant/advisor/speaker: AbbVie, Amgen, Beiersdorf, Bristol Myers Squibb, Dermavant, Janssen, LEO Pharma, Novartis, Sun Pharma, UCB.

The planners and content peer reviewers from Partners for Advancing Clinical Education and Practicing Clinicians Exchange do not have any relevant financial relationships to disclose, except Victoria Garcia-Albea, NP, DCNP as noted above.

Instructions for Credit

Learners wishing to earn CE/CME credit must: 

  1. View the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete evaluation form

The estimated time to complete this activity is 1.00 hour.


This activity has been made available online.


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Partners for Advancing Clinical Education, Practicing Clinicians Exchange or any educational supporter.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


ANCC Credit Designation

Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit

NP course advisor: Victoria Garcia-Albea, NP, DCNP, Lahey Hospital and Medical Center, Burlington, Massachusetts


AAPA Credit Designation
Joint AccreditationPartners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until January 16, 2024. PAs should only claim credit commensurate with the extent of their participation.


IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credits for learning and change.